BIO Comments on Tissue Agnostic Therapies in Oncology: Regulatory Considerations for Orphan Drug Designation
June 8, 2018
BIO submitted comments to the Food and Drug Administration’s (FDA) on Tissue Agnostic Therapies in Oncology: Regulatory Considerations for Orphan Drug Designation, following the Public Workshop on May 9, 2018.
While advances in genomics and precision medicine have significantly improved the ability to develop medicines aimed at specific molecular targets that may be present in multiple diseases and/or cancers, there is much to be learned through continued research and development. BIO appreciates the FDA taking a forward-looking approach and having early discussions about how these advances may affect other aspects of drug development and review, such as orphan drug designations.
In comments following the public workshop, BIO provided several items for the FDA’s consideration, including on the importance of the Orphan Drug Act as well as how to encourage innovation for novel therapies to treat rare diseases. BIO encourages the FDA to consider how to apply a tissue agnostic approach outside of oncology. BIO also asks the FDA to partner with stakeholders to discuss the impacts of tissue agnostic therapies on drug development and review.
Download Full Comments Below
BIO Lettter Tissue Agnostic Therapies In Oncology FDA–2018-N-0663
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
BIO submitted comments to the Food and Drug Administration’s (FDA) on Tissue Agnostic Therapies in Oncology: Regulatory Considerations for Orphan Drug Designation, following the Public Workshop on May 9, 2018.
While advances in genomics and precision medicine have significantly improved the ability to develop medicines aimed at specific molecular targets that may be present in multiple diseases and/or cancers, there is much to be learned through continued research and development. BIO appreciates the FDA taking a forward-looking approach and having early discussions about how these advances may affect other aspects of drug development and review, such as orphan drug designations.
In comments following the public workshop, BIO provided several items for the FDA’s consideration, including on the importance of the Orphan Drug Act as well as how to encourage innovation for novel therapies to treat rare diseases. BIO encourages the FDA to consider how to apply a tissue agnostic approach outside of oncology. BIO also asks the FDA to partner with stakeholders to discuss the impacts of tissue agnostic therapies on drug development and review.